Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
136
resultados
Última actualización
11/09/2026 [07:00:00]
Resumen de: AU2025232283A1
An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg/dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg/dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.
Resumen de: EP4802998A2
0001 This application discloses a continuous glucose concentration monitoring method based on a multi-working-electrode system, a continuous glucose concentration monitoring device based on a multi-working-electrode system, a computer program, a computer-readable medium and a method for preparing continuous glucose concentration monitoring device based on a multi-working-electrode system. The method includes: obtaining, by using a first working electrode, a first current value used for representing a glucose concentration of a host, and obtaining, by using a second working electrode, a second current value used for representing the glucose concentration of the host, where the first working electrode and the second working electrode are separately and independently disposed on a same substrate, and the first working electrode includes a first parameter, and the second working electrode includes a second parameter; and determining a target glucose concentration according to the first current value as well as the first parameter and/or the second parameter as well as the second current value, where the first parameter is determined based on the second parameter and the second current value. In this application, a measurement error caused by a single electrode is reduced by using the first working electrode and the second working electrode, to improve accuracy of glucose concentration monitoring, and reduce a monitoring result deviation caused by an electrode difference.
Resumen de: EP4803002A1
0001 According to one embodiment, a wearable electronic device comprises a first sensor, at least one second sensor, a memory, a display, a communication circuit and at least one processor, wherein the memory can store instructions that, when executed by the at least one processor, cause the wearable electronic device to: identify, on the basis of a first sensing value identified through the at least one second sensor, a first time point so as to measure first blood glucose data of a user wearing the wearable electronic device; use an external device at the first time point so as to display, through the display, first guide information for allowing the blood glucose of the user to be measured; measure, through the first sensor, a second sensing value indicating a first biometric signal of the user at the first time point; acquire, through the communication circuit, information indicating a first blood glucose value of the user measured at the first time point by the external device; and acquire, on the basis of the first blood glucose value and a second sensing value indicating the first biometric signal, calibration data for determining a blood glucose value of the user on the basis of sensing values indicating biometric signals of the user to be measured using the first sensor.
Resumen de: US12727758B1
A modular diagnostic system is disclosed for acquiring Raman spectral data from tear film and analyzing biochemical signatures using Artificial Intelligence (AI). The system includes a Raman excitation source, a spectral acquisition module, and a processing engine configured to perform baseline correction, feature extraction, and AI-based classification. The system enables real-time, non-invasive diagnostics for dry eye disease, diabetes, metabolic disease, pharmacologic agents, and other conditions. The system supports longitudinal tracking and EMR integration. Real-time outputs support clinical diagnosis, treatment guidance, and longitudinal monitoring.
Resumen de: WO2020067628A1
The present invention relates to a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device: includes a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use thereof, without additional work for connecting a separate transmitter, and easier maintenance; and is activated by a user's operation after the body attachment unit is attached to the body, so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.
Resumen de: US20260257014A1
Disclosed herein are systems and methods incorporating an ambulatory infusion pump and a CGM. These systems that can include software and related methods to provide improved automated insulin delivery algorithms that enable the algorithms to safely continue delivering insulin for some time periods of missing or known inaccurate glucose values.
Resumen de: US20260258368A1
0000 Methods are provided for in vitro selection of metabolic selection of metabolically selectable mammalian cells that don't require exogenous glucose and glutamine in culture. Such cells may be glycogen-storing mammalian cells, including without limitation hepatocytes. Metabolic selection provides an approach to rapidly kill non-selectable cells by withholding specific nutrients from the culture medium.
Resumen de: WO2026179772A1
A blood glucose assessment method, a user interface and a related apparatus. The blood glucose assessment method can acquire a PPG signal of a user, and then display a blood glucose result of the user obtained by assessment on the basis of the PPG signal, the blood glucose result indicating the stage at which the user falls in the progression from normal blood glucose to diabetes. The method takes into account that there is still a stage of development before normal blood glucose is converted into diabetes, thereby achieving more refined assessment of the blood glucose of users, so that the users achieve more refined self-management of blood glucose.
Resumen de: WO2026182236A1
The present disclosure provides, for example, a cell cryopreservation composition capable of protecting cells during cell freezing without substantially adding an organic solvent cell cryopreservation agent. A cell cryopreservation composition according to the present disclosure contains a sugar or a derivative thereof and/or a surfactant.
Resumen de: WO2026182442A1
Disclosed is an electronic device. The electronic device comprises: at least one sensor; memory storing a machine learning model and instructions; and at least one processor. When the instructions are individually or collectively executed by the at least one processor, the electronic device: obtains a PPG signal of a user by using the at least one sensor; performs preprocessing on the PPG signal by using a filter; obtains a power spectrum by converting the preprocessed PPG signal into frequency over time; obtains an average spectrum power for each frequency by calculating an average value of the obtained power spectrum over time; and obtains information about diabetes of the user by inputting the obtained average spectrum power for each frequency to the machine learning model.
Resumen de: US20260260730A1
A method of administering insulin includes receiving scheduled glucose time intervals and obtaining glucose data of a patient that includes glucose measurements, glucose times, and insulin dosages previously administered by the patient. The method also includes applying a set of filters to identify which of the glucose measurements associated with at least one of the scheduled time intervals are usable and which of the glucose measurements associated with the at least one scheduled time interval are unusable. The method also includes aggregating the glucose measurements associated with the at least one scheduled time interval identified as usable to determine a representative aggregate glucose measurement and determining a next recommended insulin dosage for the patient based on the representative aggregate glucose measurement and the insulin dosages previously administered by the patient.
Resumen de: EP4800534A2
The subject matter disclosed herein provides methods for presenting glucose level data. Glucose data for a patient may be received. A current glucose level and a rate of change of the current glucose level may be determined based on the received glucose data. A first interface may be displayed on a screen of a device. The first interface may include a unitary icon. The unitary icon may display the current glucose level and a visualization of the rate of change. Related apparatus, systems, techniques, and articles are also described.
Resumen de: EP4800695A2
0001 Techniques for performing application-layer security and communication over primary invitation channels are disclosed. In certain embodiments, analyte data is obtained from an analyte sensor electrically coupled to a sensor electronics module of an analyte sensor system. A secret key is established with a display device over one or more primary invitation channels. The analyte data is encrypted using the secret key. The encrypted analyte data is broadcast over the one or more primary invitation channels.
Resumen de: EP4799662A1
The invention discloses a method and system for postprandial insulin infusion based on identifiable feature of diabetic, acquiring a food image by an imaging mechanism, and analyzing the food image by the food image recognition model to obtain food data, retrieving a narrow insulin algorithm adapted to the patient's own identifiable features from the cluster of narrow insulin algorithms according to the identifiable features of the patient, for calculation of insulin infusion amount during meals, compared to the preset insulin algorithm, the narrow insulin algorithm is more applicable to the physiological characteristics and living habit of the patient, the calculated postprandial insulin infusion amount is more accurate, and is beneficial for the treatment of diabetic.
Resumen de: EP4800372A2
0001 A continuous glucose monitoring system may utilize electrode current (Isig) signals, Electrochemical Impedance Spectroscopy (EIS), and Vcntr values to optimize sensor glucose (SG) calculation in such a way as to enable reduction of the need for blood glucose (BG) calibration requests from users.
Resumen de: EP4800696A1
The present invention relates to a computer implemented training method for training a first artificial intelligence agent for glycemic control of a patient and also relates to a computer implemented method of determining an insulin dose value for a patient next to administer and for administration by an insulin administration device based on a treatment algorithm comprising a first artificial intelligence agent.
Resumen de: US12721549B1
0000 A wearable medical monitoring device comprises a microneedle array configured to extract interstitial or capillary fluid from a user, biosensors configured to detect biomarkers including glucose and complete blood count parameters such as white blood cells, red blood cells, hemoglobin, hematocrit, and platelet count, a microprocessor configured to generate biomarker data from biosensor signals, and a wireless communication module configured to transmit biomarker data to a user device for forwarding to a server. The server analyzes biomarker data using machine learning models including time-series forecasting, anomaly detection, classification, and ensemble models to detect health condition anomalies and generate alerts. The machine learning models are updated via federated learning using anonymized data. The server establishes personalized baseline values and dynamically adjusts alert thresholds based on user-specific factors and environmental context.
Resumen de: MA70860A1
The invention concerns a smart ring designed to monitor the user's vital parameters and predict the risk of developing acute coronary syndrome (ACS). This watch incorporates advanced signal processing techniques and sophisticated algorithms to analyze heart rate variability as well as total cholesterol, blood glucose and blood pressure levels associated with acute coronary events. The vital data is sent to a server via an NB-IoT communication module, and visualized using a web interface. An integrated artificial intelligence model continuously analyzes the processed data to identify patterns indicative of ACS. If a high risk of ACS is detected, the ring emits visual and audible alerts, prompting the user to seek immediate medical attention. In addition, a user interface offers the possibility of viewing data and forecasts in real time, enabling continuous, proactive monitoring. This invention enables early detection of ACS thanks to improved analysis of vital parameters and the use of artificial intelligence for continuous real-time monitoring, thus improving the safety of preventive medical measures and the well-being of the user.
Resumen de: US20260249003A1
The disclosed relates to an insulin syringe replacement system for an insulin pump. The system comprises: a control unit for controlling the operation of the insulin pump; an operation unit for performing an initialization setting operation when an insulin syringe is replaced under the control of the control unit; and a battery unit for supplying power to the control unit and the operation unit; a housing unit for mounting the insulin syringe; and a sensor unit for confirming whether a stopper of the insulin syringe mounted on the housing unit is coupled and notifying the control unit of the confirmation, wherein the control unit controls the operation unit to perform the initialization setting operation only after receiving the confirmation from the sensor unit that the stopper of the insulin syringe mounted on the housing unit is coupled.
Resumen de: US20260253702A1
The system according to the embodiment comprises a collection unit, an analysis unit, and a notification unit. The collection unit collects vital data. The analysis unit analyzes data collected by the collection unit and predicts changes in blood glucose levels. The notification unit notifies the timing of insulin injection based on the changes in blood glucose levels predicted by the analysis unit. The notification unit notifies the user and contacts when hypoglycemia is detected.
Resumen de: WO2026175096A1
Provided in the present application are a blood glucose monitoring method and a related apparatus. In the method, the blood glucose level at a first moment can be acquired on the basis of a glucose concentration in interstitial fluid at the first moment, a glucose concentration in the interstitial fluid within a time period before the first moment and a glucose concentration in the interstitial fluid within a time period after the first moment. In the present application, the glucose concentration in the interstitial fluid within the time period after the first moment is taken into consideration, and an additional time period is provided for the diffusion of glucose between the interstitial fluid and blood; therefore, when the blood glucose level drastically changes, the glucose concentration in the interstitial fluid more closely approximates the blood glucose level, and thus the accuracy of blood glucose monitoring can be improved.
Resumen de: US20260249007A1
0000 A technique for treating diabetes that recognizes patient insulin sensitivity is a time-varying physiological parameter. The described techniques for treating diabetes include measuring interstitial fluid glucose concentration, reading insulin delivery data, determining patient insulin sensitivity based on the interstitial fluid glucose concentration and insulin delivery data, and a time-varying physiological parameter, and dispensing an insulin dose from an insulin delivery device based on the determined patient insulin sensitivity.
Resumen de: AU2026214068A1
A stool resuspension solution comprising a hemoglobin stabilization reagent is provided. In some embodiments, the hemoglobin stabilization reagent may be an osmolyte, a polyvalent cation, a sugar or polysaccharide and, optionally, a polyvalent cation, a protoporphyrin,or an HRP stabilization component and, optionally, a polyvalent cation. A method of stabilizing hemoglobin in a stool sample in the solution is also provided, as well as a sample collection device containing the solution. ug u g
Resumen de: AU2025224752A1
Exemplary embodiments relate to drug delivery devices, such as automated insulin delivery (AMD) devices. The described methods and apparatuses allow an AMD device to be initialized and/or operated with little or no user input. Exemplary logic initializes the AMD device to operate with known-safe drug delivery parameters that leverage the AMD device's ability to monitor blood glucose levels at short intervals and continuously deliver small amounts of insulin. The AMD then rapidly adapts the parameters and system constraints based on current and historical glucose measurements. Further embodiments provide for the detection of events that result in disturbances to glucose control, and to adaptation of alert frequency based on user behavior.
Nº publicación: AU2025213042A1 27/08/2026
Solicitante:
CCS MEDICAL INC
CCS MEDICAL, INC.
Resumen de: AU2025213042A1
Disclosed herein is a healthcare management system and method utilizing machine learning based predictive analytics to improve patient adherence rates for chronic care management (e.g., diabetes). An example system may include a computing device configured to establish a customer analytical record to synthetize over a plurality of selected attributes to form a patient centric view of patient behaviors, attitude, characteristics based upon data related to chronic disease state management and social determinants of health, consumer experience to determine, using a predictive artificial intelligence model, a patient's predictive adherence for next 1-3 months, and determine tailored intervention plans to engage patients for continuing adherence.
BOPI
Sede Electrónica
